No Prescription |
 |
 | ||
|
Aprecap EMEND |
|
| ||
No Prescription » Prescription Drugs 2 » Aprecap EMEND Aprepitant is used with other medications to help prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). This medication is also used to prevent nausea and vomiting after surgery. Aprepitant works by blocking one of the body's natural substances (substance P/neurokinin 1) that causes vomiting.This medication will not treat nausea or vomiting if you already have it. Contact your doctor for further instructions if you are experiencing nausea or vomiting.How to use Aprepitant OralRead the Patient Information Leaflet available from your pharmacist before you start taking this medication and each time you get a refill. If you have any questions consult your doctor or pharmacist.Take this medication by mouth with or without food. To prevent nausea and vomiting caused by cancer chemotherapy you will usually take the first dose 1 hour before treatment. On the following 2 days you will usually take the dose once daily in the morning or as directed by your doctor. If you are taking this medication to prevent nausea and vomiting after surgery you will usually take one dose of 40 milligrams before surgery.Dosage is based on your medical condition (depending on whether you are taking this medication before cancer chemotherapy or surgery) and response to treatment. It is important to follow your doctor's instructions for when to take each dose how long to keep taking it and the strength (number of milligrams) of each dose. If you have any questions consult your doctor or pharmacist.Tell your doctor if you develop nausea or vomiting.What conditions does this medication treat?Aprepitant Oral is used to treat the following:Prevent Nausea and Vomiting After Surgery Prevent Nausea and Vomiting from Cancer Chemotherapy Buy Aprecap EMEND and other Prescription Drugs 2 products online at Medstore. Buy Online at Medstore - Click Here!
About Aprecap EMEND: Product Type: Prescription Drugs 2 Aprecap ( EMEND Generic Aprepitant ) Aprecap (EMEND Generic Aprepitant) EMEND Generic Aprepitant 125/80mg 3 Capsules 2 x 3 Capsules 3 x 3 Capsules EMEND Generic Aprepitant Aprecap
View more Prescription Drugs 2 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
